Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II first-line thalidomide + PegIntron + IL-2 in metastatic melanoma
2004-005166-20Phase 2Completed
- Sponsor
- University Hospital Odense
- Start
- Apr 2005
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of thalidomide, peginterferon alfa-2b, aldesleukin in melanoma, sponsored by University Hospital Odense. Started Apr 2005; status: completed.
02
Drugs
thalidomidepeginterferon alfa-2baldesleukin
03
Conditions
melanoma
Beyond the preview
Go deeper on 2004-005166-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-005166-20.